Protein synthesis inhibitors, in synergy with 5-azacytidine, restore sodium/iodide symporter gene expression in human thyroid adenoma cell line, KAK-1, suggesting trans-active transcriptional repressor

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 3, 2007, Pages 1080-1087

  Li, Wei ^b   Venkataraman, Gopalakrishnan M ^b   Ain, Kenneth B ^a  

^a UNIVERSITY OF KENTUCKY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANISOMYCIN; AZACITIDINE; BUTYRIC ACID; CYCLOHEXIMIDE; DEOXYRIBONUCLEASE I; EMETINE; HISTONE H4; LUCIFERASE; MESSENGER RNA; PROTEIN SYNTHESIS INHIBITOR; PUROMYCIN; SODIUM IODIDE SYMPORTER;

ACETYLATION; ARTICLE; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; GENE DELETION; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THYROID ADENOMA; TUMOR CELL LINE;

EID: 33947545622     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2106     Document Type: Article

References (38)

1. Robbins J, Merino MJ, Boice Jr JD, Ron E, Ain KB, Alexander HR, Norton JA, Reynolds J 1991 Thyroid cancer: a lethal neoplasm. Ann Intern Med 115:133-147
2. Pohlenz J, Refetoff S 1999 Mutations in the sodium/iodide symporter (NIS) gene as a cause for iodide transport defects and congenital hypothyroidism. Biochimie (Paris) 81:469-476
3. Pohlenz J, Duprez L, Weiss RE, Vassart G, Refetoff S, Costagliola S 2000 Failure of membrane targeting causes the functional defect of two mutant sodium iodide symporters. J Clin Endocrinol Metab 85:2366-2369
4. Venkataraman GM, Yatin M, Marcinek R, Ain KB 1999 Restoration of iodide uptake in dedifferentiated thyroid carcinoma: relationship to human Na+/I-symporter gene methylation status. J Clin Endocrinol Metab 84:2449-2457
5. Santi DV, Norment A, Garrett CE 1984 Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc Natl Acad Sci USA 81:6993-6997
6. Gabbara S, Bhagwat AS 1995 The mechanism of inhibition of DNA (cytosine-5-)-methyltransferases by 5-azacytosine is likely to involve methyl transfer to the inhibitor. Biochem J 307:87-92
7. Juttermann R, Li E, Jaenisch R 1994 Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91:11797-11801
8. Sawa H, Murakami H, Ohshima Y, Murakami M, Yamazaki I, Tamura Y, Mima T, Satone A, Ide W, Hashimoto I, Kamada H 2002 Histone deacetylase inhibitors such as sodium butyrate and trichostatin A inhibit vascular endothelial growth factor (VEGF) secretion from human glioblastoma cells. Brain Tumor Pathol 19:77-81
9. Zhou JF, Liu WL, Chen G, Lu YP, Ma D 2002 [Molecular mechanism of inhibition of sodium butyrate on activation of tumor associated aromatase promoters.] Ai Zheng 21:1283-1287
10. Nagy L, Kao HY, Chakravarti D, Lin RJ, Hassig CA, Ayer DE, Schreiber SL, Evans RM 1997 Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell 89:373-380
11. Venkatasubbarao K, Ammanamanchi S, Brattain MG, Mimari D, Freeman JW 2001 Reversion of transcriptional repression of Sp1 by 5 aza-2′ deoxycytidine restores TGF-β type II receptor expression in the pancreatic cancer cell line MIA PaCa-2. Cancer Res 61:6239-6247
12. Yang J, Kawai Y, Hanson RW, Arinze IJ 2001 Sodium butyrate induces transcription from the G α(i2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. J Biol Chem 276:25742-25752
13. Palyi I, Peter I, Daubner D, Vincze B, Lorincz I 1993 Establishment, characterization and drug sensitivity of a new anaplastic thyroid carcinoma cell line (BHT-101). Virchows Arch B Cell Pathol Incl Mol Pathol 63:263-269
14. Ain KB, Taylor KD 1994 Somatostatin analogs affect proliferation of human thyroid carcinoma cell lines in vitro. J Clin Endocrinol Metab 78:1097-1102
15. Kramer JA, Krawetz SA 1997 Determining the potentiative state of a chromatin domain. Biotechniques 22:879-882
16. Venkataraman GM, Yatin M, Ain KB 1998 Cloning of the human sodium-iodide symporter promoter and characterization in a differentiated human thyroid cell line, KAT-50. Thyroid 8:63-69
17. Zarnegar R, Brunaud L, Kanauchi H, Wong M, Fung M, Ginzinger D, Duh QY, Clark OH 2002 Increasing the effectiveness of radioactive iodine therapy in the treatment of thyroid cancer using Trichostatin A, a histone deacetylase inhibitor. Surgery 132:984 -990; discussion 990
18. Furuya F, Shimura H, Suzuki H, Taki K, Ohta K, Haraguchi K, Onaya T, Endo T, Kobayashi T 2004 Histone deacetylase inhibitors restore radioiodide uptake and retention in poorly differentiated and anaplastic thyroid cancer cells by expression of the sodium/iodide symporter thyroperoxidase and thyroglobulin. Endocrinology 145:2865-2875
19. Fortunati N, Catalano MG, Arena K, Brignardello E, Piovesan A, Boccuzzi G 2004 Valproic acid induces the expression of the Na+/I- symporter and iodine uptake in poorly differentiated thyroid cancer cells. J Clin Endocrinol Metab 89:1006-1009
20. Kitazono M, Robey R, Zhan Z, Sarlis NJ, Skarulis MC, Aikou T, Bates S, Fojo T 2001 Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na(+)/I(-) symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells. J Clin Endocrinol Metab 86:3430-3435
21. Puppin C, D'Aurizio F, D'Elia AV, Cesaratto L, Tell G, Russo D, Filetti S, Ferretti E, Tosi E, Mattei T, Pianta A, Pellizzari L, Damante G 2005 Effects of histone acetylation on sodium iodide symporter promoter and expression of thyroid-specific transcription factors. Endocrinology 146:3967-3974
22. Pochin EE 1971 Radioiodine therapy of thyroid cancer. Semin Nucl Med 1:503-515
23. Lea MA, Randolph VM, Hodge SK 1999 Induction of histone acetylation and growth regulation in eryrthroleukemia cells by 4-phenylbutyrate and structural analogs. Anticancer Res 19:1971-1976
24. Nakano K, Mizuno T, Sowa Y, Orita T, Yoshino T, Okuyama Y, Fujita T, Ohtani-Fujita N, Matsukawa Y, Tokino T, Yamagishi H, Oka T, Nomura H, Sakai T 1997 Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. J Biol Chem 272:22199-22206
25. Reeves R, Gorman CM, Howard B 1985 Minichromosome assembly of non-integrated plasmid DNA transfected into mammalian cells. Nucleic Acids Res 13:3599-3615
26. Smith CL, Hager GL 1997 Transcriptional regulation of mammalian genes in vivo. A tale of two templates. J Biol Chem 272:27493-27496
27. Riedel C, Levy O, Carrasco N 2001 Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 276:21458-21463
28. Schmitt TL, Espinoza CR, Loos U 2001 Transcriptional regulation of the human sodium/iodide symporter gene by Pax8 and TTF-1. Exp Clin Endocrinol Diabetes 109:27-31
29. Pasca di Magliano M, Di Lauro R, Zannini M 2000 Pax8 has a key role in thyroid cell differentiation. Proc Natl Acad Sci USA 97:13144-13149
30. Shafer LM, Slice LW 2005 Anisomycin induces COX-2 mRNA expression through p38(MAPK) and CREB independent of small GTPases in intestinal epithelial cells. Biochim Biophys Acta 1745:393-400
31. Bai J, Cederbaum AI 2006 Cycloheximide protects Hepg2 cells from serum withdrawal induced apoptosis by decreasing p53 and phosphorylated p53 levels. J Pharmacol Exp Ther 319:1435-1443
32. Wu Y, Rozenfeld S, Defferrard A, Ruggiero K, Udall JA, Kim H, Llewellyn DJ, Dennis ES 2005 Cycloheximide treatment of cotton ovules alters the abundance of specific classes of mRNAs and generates novel ESTs for microarray expression profiling. Mol Genet Genomics 274:477-493
33. Hershko DD, Robb BW, Wray CJ, Luo GJ, Hasselgren PO 2004 Superinduction of IL-6 by cycloheximide is associated with mRNA stabilization and sustained activation of p38 map kinase and NF-κB in cultured caco-2 cells. J Cell Biochem 91:951-961
34. Edwards DR, Mahadevan LC 1992 Protein synthesis inhibitors differentially superinduce c-fos and c-jun by three distinct mechanisms: lack of evidence for labile repressors. EMBO J 11:2415-2424
35. Pontecorvi A, Tata JR, Phyillaier M, Robbins J 1988 Selective degradation of mRNA: the role of short-lived proteins in differential destabilization of insulin-induced creatine phosphokinase and myosin heavy chain mRNAs during rat skeletal muscle L6 cell differentiation. EMBO J 7:1489-1495
36. Joiakim A, Mathieu PA, Elliott AA, Reiners Jr JJ 2004 Superinduction of CYP1A1 in MCF10A cultures by cycloheximide, anisomycin, and puromycin: a process independent of effects on protein translation and unrelated to suppression of aryl hydrocarbon receptor proteolysis by the proteasome. Mol Pharmacol 66:936-947
37. Vazquez-Macias A, Ruiz-Mendoza AB, Fonseca-Sanchez MA, Briones-Orta MA, Macias-Silva M 2005 Downregulation of Ski and SnoN co-repressors by anisomycin. FEBS Lett 579:3701-3706
38. Ohmori M, Endo T, Harii N, Onaya T 1998 A novel thyroid transcription factor is essential for thyrotropin-induced up-regulation of Na+/I- symporter gene expression. Mol Endocrinol 12:727-736